|Awarded On||August 21, 2019|
|Title||Development of a novel class of PRC2 inhibitors comprised of mirror image RNA|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas A&M University|
|Principal Investigator/Program Director||Jonathan Sczepanski|
|Cancer Sites||Breast, Lymphoma, Prostate|
*Pending contract negotiation
The Polycomb Repressive Complex 2 (PRC2) is a transcriptional repressor that regulates several crucial developmental and physiological processes in the cell. Recently, scientists have identified a strong link between PRC2 and cancer; several cancer types exhibit dysregulation and dysfunction of PRC2 proteins. For example, PRC2 overexpression has been linked to breast cancer, prostate cancer and melanomas, and high levels of PRC2 were shown to correlate with an aggressive and advanced disease state in each of these cancer types. As a result, substantial efforts have been devoted to developing PRC2 inhibitors as cancer therapeutics, the vast majority of which are small molecules targeting the ...